Our impact
Drugging the 'undruggable'
An innovative but risky discovery research project that you helped fund in 2013 has allowed Dr Laura Soucek to develop a new cancer treatment and prove that it was ready for clinical trials.
A lifesaving cancer drug
Curestarters funded crucial early research that helped launch a revolutionary drug, that has already been used to treat over 140,000 cancer patients worldwide Clinical trials are now ongoing to see if it could save even more.
Deciphering the 'barcode' of prostate cancer
A research project that our supporters helped us fund in 1999 kick-started decades of work by Professor Ros Eeles, which has culminated in the biggest prostate cancer screening trial for 20 years.
Shining a light on cancer
Thanks to Curestarter support in the early 90s, Professor Stephen Bown was able to further study an experimental laser treatment for cancer which has since been approved by the NHS for use in treating oesophageal, skin, and oral cancers.
Five key risk factors for endometrial cancer that you should know about
Thanks to your support Dr Tracy O’Mara and her team in Australia have made an important breakthrough in understanding risk factors for endometrial cancer.
Tackling the 'guardian of the genome'
You funded important biomedical research by Professor John Spencer that has helped lead to a ground-breaking new cancer treatment entering clinical trials.
Helping to diagnose rare genetic diseases
Your support helped Professor Kevin Hiom discover a new gene which was involved in the development of a rare genetic disease called Fanconi anemia.
Repurposing a diabetes drug for cancer treatment
Your support helped a drug for type 2 diabetes be tested in over 100 clinical trials for treatment and prevention of cancer.
Donate today to start new cures
Be part of the united effort to stop lives being cut short by cancer.
Become a Curestarter with just one click.
Sign up to receive our monthly newsletter, jam-packed with answers to your cancer research questions, updates on our latest news and breakthroughs, and opportunities to support our pioneering research.